OBJECTIVES: Vutrisiran and patisiran are approved RNA interference (RNAi) therapies that demonstrate comparable efficacy in halting or reversing progression of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. Vutrisiran is administered subcutaneously every-3-months (Q3M) and patisiran intravenously every-3-weeks (Q3W). Here, the differential impacts of these two therapies on healthcare resource use and indirect productivity loss costs are estimated.

METHODS: An economic analysis (societal perspective) was performed to estimate how the administration profiles of vutrisiran and patisiran impact healthcare resource use and indirect productivity loss costs in the United Kingdom. For healthcare resource use, the model considered resources required and associated costs for treatment administration (excluding drug acquisition) and treatment-related patient monitoring; for productivity losses, the model considered short-term reductions in work productivity associated with the dosing schedules of vutrisiran and patisiran. As comparable clinical outcomes are achieved with both treatments, other direct healthcare costs (for disease management and drug acquisition) were assumed equivalent between vutrisiran and patisiran.

RESULTS: Over ten years, from a mean starting age of 60 years, total per-patient administration costs for vutrisiran and patisiran were £127/year and £7,699/year (difference: £7,572/year), respectively, reflecting reduced resource use requirements for vutrisiran administration. Among employed patients, we estimated 3.9 hours/year of lost work activity per-patient with vutrisiran versus 16.9 hours/year with patisiran. Based on age-specific wages adjusted for employment activity, this translates to per-patient indirect costs of £41/year for vutrisiran and £179/year for patisiran.

CONCLUSIONS: Vutrisiran and patisiran provide comparable efficacy in halting or reversing progression of hATTR amyloidosis with polyneuropathy, while vutrisiran offers additional economic advantages regarding direct healthcare costs, health-service benefits, and societal benefits. These benefits result from the administration profile of vutrisiran, as Q3M subcutaneous dosing of vutrisiran (vs. Q3W IV dosing of patisiran) requires less healthcare resource consumption and is estimated to be less disruptive to patients’ work productivity.